{
  "trial_id": "NCT02664441",
  "trial_group": "obesity",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, BMI, history of craniopharyngioma or other hypothalamic tumor, hypothalamic lesion documentation, time since surgical or radiation treatment, weight stability over 3 months, hormone replacement stability, renal function (GFR), history of gastroparesis, history of pancreatitis or gallstones, family history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma, insulin-treated diabetes mellitus status, HbA1c levels, presence of chronic serious medical conditions, calcitonin levels, use of weight loss medications, blood donation history, warfarin use, use of GLP1 receptor agonists, thyroid disorder status, adrenal insufficiency status, history of bariatric surgery, pregnancy status, lactation status, adherence likelihood, contraindications to MRI.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Body Mass Index",
          "BMI"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "history of craniopharyngioma or other hypothalamic tumor",
        "hypothalamic lesion documentation",
        "time since surgical or radiation treatment",
        "weight stability over 3 months",
        "hormone replacement stability",
        "renal function (GFR)",
        "history of gastroparesis",
        "history of pancreatitis or gallstones",
        "family history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma",
        "insulin-treated diabetes mellitus status",
        "HbA1c levels",
        "presence of chronic serious medical conditions",
        "calcitonin levels",
        "use of weight loss medications",
        "blood donation history",
        "warfarin use",
        "use of GLP1 receptor agonists",
        "thyroid disorder status",
        "adrenal insufficiency status",
        "history of bariatric surgery",
        "pregnancy status",
        "lactation status",
        "adherence likelihood",
        "contraindications to MRI"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Weight, Height, Glucose Tolerance, Insulin Resistance, Hormone Replacement Status, Energy Expenditure, Activity Level, Energy Intake, ",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Body Mass Index",
          "Body Mass Index"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Weight",
        "Height",
        "Glucose Tolerance",
        "Insulin Resistance",
        "Hormone Replacement Status",
        "Energy Expenditure",
        "Activity Level",
        "Energy Intake"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Hypothalamic obesity diagnosis, Craniopharyngioma diagnosis, Other hypothalamic tumor diagnosis, Age at diagnosis, Duration of hypothalamic obesity, Duration of hormone replacement therapy, Family history of metabolic disorders, History of gastroparesis, History of pancreatitis, History of gallstones, History of multiple endocrine neoplasia type 2, History of familial medullary thyroid carcinoma, History of insulin-treated diabetes mellitus, History of poorly controlled type 2 diabetes, History of cardiovascular disease, History of malignancy, History of hematologic disorder, History of complicated syndromic disorder, History of psychiatric disorders.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Body Mass Index",
          "Body Mass Index"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Hypothalamic obesity diagnosis",
        "Craniopharyngioma diagnosis",
        "Other hypothalamic tumor diagnosis",
        "Age at diagnosis",
        "Duration of hypothalamic obesity",
        "Duration of hormone replacement therapy",
        "Family history of metabolic disorders",
        "History of gastroparesis",
        "History of pancreatitis",
        "History of gallstones",
        "History of multiple endocrine neoplasia type 2",
        "History of familial medullary thyroid carcinoma",
        "History of insulin-treated diabetes mellitus",
        "History of poorly controlled type 2 diabetes",
        "History of cardiovascular disease",
        "History of malignancy",
        "History of hematologic disorder",
        "History of complicated syndromic disorder",
        "History of psychiatric disorders"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, BMI, weight, height, diagnosis (craniopharyngioma or other hypothalamic tumor), time since surgery or radiation treatment, hormone replacement status, presence of comorbidities (renal impairment, gastroparesis, pancreatitis, gallstones, diabetes, cardiovascular disease, malignancy, hematologic disorder, complicated syndromic disorder, psychiatric disorders), family history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma, calcitonin level, thyroid function, adrenal function.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Body Mass Index",
          "BMI"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "weight",
        "height",
        "diagnosis (craniopharyngioma or other hypothalamic tumor)",
        "time since surgery or radiation treatment",
        "hormone replacement status",
        "presence of comorbidities (renal impairment, gastroparesis, pancreatitis, gallstones, diabetes, cardiovascular disease, malignancy, hematologic disorder, complicated syndromic disorder, psychiatric disorders)",
        "family history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma",
        "calcitonin level",
        "thyroid function",
        "adrenal function"
      ]
    }
  }
}